Procarta receives carb-x award of up to $9.2 million
FOR DEVELOPMENT OF NEW CLASS OF ANTIBIOTICS TO COMBAT LIFE-THREATENING DRUG-RESISTANT PATHOGENS Stevenage, UK,…read more
Procarta Biosystems is a spin-out from one of Europe’s leading microbiology departments at the John Innes Centre. The company, formed in early 2008, is investigating a novel approach to counter antibiotic resistance and defeat infectious diseases using a DNA decoy technique, which aims to restore antibiotic efficacy against resistant superdrugs, such as methicillin-resistent Staphylococcus aureus (MRSA) and vancomycin-resistant Entercoccus (VRE).
Accessing the skills in the John Innes Centre, Procarta is also able to offer a contract research service creating and improving Streptomyces strains for heterologous production.
Associated Fund UK Innovation & Science Seed Fund
Sector Medical / Biotechnology